Parteck® SRP 80, our new functional excipient based on polyvinyl alcohol (PVA), provides reliable sustained drug delivery over long release periods. Its matrix diffusion technology helps increase the efficacy and bioavailability of your compound while reducing side effects and the risk of dose dumping.
Parteck® SRP 80 is well suited for direct compression processes and helps accelerate your formulation work—from simplified feasibility and development to rapid and cost-efficient manufacturing.
Benefits of Parteck® SRP 80:
For more detailed information about Parteck® SRP 80, see the flyer in the related resources section.
Merck today introduced Parteck® SRP 80, a new functional excipient for oral sustained-release formulations.